COPD合并2型糖尿病患者使用SGLT2抑制剂与肺癌风险降低相关
一项基于全国健康保险数据库的队列研究纳入14,927例≥40岁COPD合并2型糖尿病成人,比较起始SGLT2抑制剂与磺脲类药物的结局。中位随访2.97年,SGLT2抑制剂组4年肺癌累积发生率为1.6%,磺脲类组为2.7%;起始SGLT2抑制剂与肺癌风险降低相关(IPTW HR 0.73,95%CI 0.60-0.90),并与重度COPD急性加重和全因死亡风险降低相关。
要点
- COPD合并2型糖尿病患者起始SGLT2抑制剂与肺癌风险降低相关(IPTW HR 0.73)。
- SGLT2抑制剂还与重度COPD急性加重风险降低相关(IPTW HR 0.77)。
- SGLT2抑制剂与全因死亡风险降低相关(IPTW HR 0.81)。
核心结论
- 在COPD合并2型糖尿病的全国队列中,起始SGLT2抑制剂相比起始磺脲类药物与肺癌、COPD急性加重和全因死亡风险降低相关。
研究设计与样本
- 共纳入14,927例患者,其中5,651例接受SGLT2抑制剂,9,276例接受磺脲类药物。
- 主要结局为肺癌发生,次要结局为重度COPD急性加重和全因死亡;中位随访2.97年。
主要发现
- 随访期间共发生234例肺癌事件。
- SGLT2抑制剂组4年肺癌累积发生率为1.6%,磺脲类组为2.7%。
- 起始SGLT2抑制剂与肺癌风险降低相关(IPTW HR 0.73;95%CI 0.60-0.90)。
- SGLT2抑制剂使用与重度COPD急性加重风险降低相关(IPTW HR 0.77;95%CI 0.71-0.83)。
- SGLT2抑制剂使用与全因死亡风险降低相关(IPTW HR 0.81;95%CI 0.75-0.88)。
临床怎么用
- 对于COPD合并2型糖尿病患者,选择降糖药物时可考虑SGLT2抑制剂,因其与肺癌、重度急性加重和全因死亡风险降低相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is associated with an increased risk of lung cancer, and type 2 diabetes mellitus (T2DM) is a common comorbidity in patients with COPD. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have pleiotropic effects beyond glucose lowering. However, their association with lung cancer risk in patients with COPD and T2DM remains uncertain. RESEARCH QUESTION: Is SGLT2 inhibitor initiation associated with a lower risk of incident lung cancer in patients with COPD and T2DM? STUDY DESIGN AND METHODS: We conducted a nationwide population-based cohort study using the National Health Insurance Database, including adults ≥ 40 years of age with COPD and T2DM who initiated SGLT2 inhibitors or sulfonylureas between September 2014 and December 2023. The primary outcome was incident lung cancer. Secondary outcomes included severe COPD exacerbation and all-cause mortality. RESULTS: Among 14,927 patients (5,651 receiving SGLT2 inhibitors and 9,276 receiving sulfonylureas), 234 incident lung cancer events occurred during a median follow-up of 2.97 years. The 4-year cumulative incidence of lung cancer was 1.6% in the SGLT2 inhibitor group and 2.7% in the sulfonylurea group. Initiation of SGLT2 inhibitors was associated with a lower risk of incident lung cancer compared with initiation of sulfonylureas (inverse probability of treatment weighting [IPTW] hazard ratio [HR], 0.73; 95% CI, 0.60-0.90). SGLT2 inhibitor use also was associated with reduced risk of severe COPD exacerbations (IPTW HR, 0.77; 95% CI, 0.71-0.83) and all-cause mortality (IPTW HR, 0.81; 95% CI, 0.75-0.88). INTERPRETATION: Our results show that in this nationwide cohort of patients with COPD and T2DM, initiation of SGLT2 inhibitors was associated with lower risks of lung cancer, COPD exacerbation, and all-cause mortality compared with initiation of sulfonylureas.
引用
- Kang, Yoo, Lee, et al. Reduced Risk of Lung Cancer Associated With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With COPD and Type 2 Diabetes Mellitus. Chest. 2026. PMID: 42508725. doi:10.1016/j.chest.2026.07.5208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。